SCHEMBL4565897

SCHEMBL4565897

CNc1ncc2cc(-c3cc(NC(=O)Nc4cnn(C(C)(C)C)c4C)c(F)cc3Cl)c(=O)n(C)c2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.60
RAF1 P04049 3/20 0.60
SRC P12931 7/20 0.47
FGFR1 P11362 4/20 0.47
EGFR P00533 3/20 0.47
SIK2 Q9H0K1 3/20 0.46
STK4 Q13043 1/20 0.46
STK3 Q13188 1/20 0.46
STK26 Q9P289 1/20 0.46
STK24 Q9Y6E0 1/20 0.46
ABL1 P00519 6/20 0.41
MAPK14 Q16539 6/20 0.41
KRAS P01116 2/20 0.41
KDR P35968 2/20 0.41
MAPK13 O15264 1/20 0.41
FYN P06241 1/20 0.41
ARAF P10398 1/20 0.41
EPHA2 P29317 1/20 0.41
CSK P41240 1/20 0.41
MAPK8 P45983 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422461 0.92 BRAF (0.71) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5061661 0.91 BRAF (0.59) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4433688 0.88 RAF1 (0.46) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5061721 0.87 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4429158 0.86 BRAF (0.55) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5065211 0.86 BRAF (0.49) BRAFRAF1SRCFGFR1ABL1
SCHEMBL4421936 0.83 BRAF (0.71) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4287266 0.82 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR
SCHEMBL4419489 0.82 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR
SCHEMBL5062818 0.82 BRAF (0.58) BRAFRAF1SRCFGFR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885SRC 417/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885SRC 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.